High-cost drugs accounted for 41.6 per cent of patented medicine sales in 2017, up from 8.3 per cent a decade earlier, according to the Patented Medicine Prices Review Board’s latest annual report. Federal Health Minister Ginette Petitpas Taylor tabled the report, which also illustrated a rise in the sales of patented medicines in 2017. Sales […]
The vast majority (87 per cent) of physicians said the knowledge that a patient has private drug coverage affects their prescribing behaviour, according to a survey by Merck Canada Inc. More specifically, the survey found 26 per cent of general practitioners and 28 per cent of specialists believe this knowledge widens the treatment options available to the patient. Other effects […]
How do the following sound as headlines for the cover of Benefits Canada? Are they likely to make the cut any time soon? • “My boss is 89” • “Remember when we went to the doctor’s office?” • “On-the-job diagnosis” • “Machines don’t need benefits” • “Artificial benefits” • “Shareholders elect first AI CEO (actuary’s […]
There were almost 4,000 opioid-related deaths in Canada in 2017, according to Health Canada statistics released in June. Meanwhile, in the United States, a new survey by the National Business Group on Health found 60 per cent of large employers had experienced at least one issue stemming from prescription opioid misuse or abuse in the workplace. Forty […]
While a national pharmacare program is likely to come with a tax hike, will that cost be balanced out by savings on prescription drugs and private drug spending? In a presentation to be delivered Friday to provincial and territorial premiers, former parliamentary budget officer Kevin Page is expected to be straightforward about the costs of a cross-country, publicly […]
Former federal budget watchdog Kevin Page will deliver a blunt message to premiers this week about the costs of a future national pharmacare program: if Canadians want one, taxes will have to go up. Page, who now heads a University of Ottawa think tank, will walk through the numbers Friday when he gives a presentation […]
Ontario’s new Conservative government has announced changes to the province’s youth pharmacare program to make it second payer for Ontarians under age 25 who have coverage through private benefits plans. “Today, our government is announcing our intent to fix the OHIP+ program by focusing benefits on those who do not have existing prescription drug benefits,” […]
When it instituted random drug testing last year, the Toronto Transit Commission was eager to ensure its employees knew what it expected of them. To get the message out, the transit authority mailed a handbook last year to the home of every employee and published it online so all workers would be fully aware of […]
A recent study examining the potential savings determined that, based on the uptake of available biosimilars in Organisation for Economic Co-operation and Development countries, Canada could save between eight per cent and 43 per cent. Although Health Canada approved Inflectra, the first biosimilar for Remicade, in 2014 to treat a number of conditions, the drug […]
Orphan drugs represent a significant and growing share of new pharmaceutical entrants in Canada, according to a new report from the Patented Medicine Prices Review Board. At 54 per cent of new pharmaceuticals entering the market in 2015 and 42 per cent in 2016, orphan drugs have seen a significant rise from an average of 33 […]